CombiGene AB (SE:LARK)
:LARK
Top Page
CombiGene AB
(LARK)
Select Model
Select Model
Rating:43Neutral
Price Target:
kr2.00
▼(-14.89% Downside)
Action:ReiteratedDate:12/30/25
The score is held down primarily by deteriorating financial performance (sharp revenue decline, widening losses, and continued cash burn), partially offset by a low-leverage/debt-free balance sheet. Technical indicators also reflect weak momentum, while valuation support is limited by a loss-making P/E despite a high stated dividend yield.
Positive Factors
Debt-Free Balance Sheet
A debt-free balance sheet reduces financial risk and refinancing pressure, providing flexibility for future strategic investments.
Negative Factors
Revenue Decline
A sharp decline in revenue indicates challenges in maintaining sales momentum, which could hinder long-term growth and market competitiveness.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-Free Balance Sheet
A debt-free balance sheet reduces financial risk and refinancing pressure, providing flexibility for future strategic investments.
Read all positive factors
CombiGene AB (LARK) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr41.19M
Dividend Yield8.47%
Average Volume (3M)41.41K
Price to Earnings (P/E)―
Beta (1Y)-0.03
Revenue Growth-94.12%
EPS Growth-25.83%
CountrySE
Employees1
SectorFinancial
Sector Strength70
IndustryAsset Management
Share Statistics
EPS (TTM)0.01
Shares Outstanding19,801,197
10 Day Avg. Volume70,026
30 Day Avg. Volume41,406
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)0.66
Price to Sales (P/S)144.56
P/FCF Ratio-1.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
CombiGene AB Business Overview & Revenue Model
Company Description
Lärkberget AB (publ) operates as an investment company. It is involved in Direct investments in low-risk instruments; Financial investments; Direct investments in unlisted profitable companies; and Reverse acquisition platform. The company was for...
How the Company Makes Money
CombiGene makes money primarily through the development and commercialization of its gene therapy products. The company generates revenue by partnering with larger pharmaceutical companies for the co-development, licensing, and distribution of its...
CombiGene AB Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
56
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.52M | 326.00K | 5.54M | 26.70M | 84.04M | 10.83M |
| Gross Profit | -3.54M | -46.78M | -21.29M | -19.20M | 15.16M | 8.33M |
| EBITDA | -23.75M | -34.22M | -35.98M | -5.86M | 23.56M | -25.66M |
| Net Income | -35.45M | -44.88M | -35.66M | -6.16M | 20.96M | -30.77M |
Balance Sheet | ||||||
| Total Assets | 61.19M | 75.88M | 120.61M | 158.22M | 166.22M | 79.41M |
| Cash, Cash Equivalents and Short-Term Investments | 60.28M | 73.75M | 101.44M | 131.78M | 136.74M | 48.90M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 5.91M | 4.30M | 4.16M | 6.10M | 7.94M | 7.98M |
| Stockholders Equity | 55.28M | 71.58M | 116.46M | 152.12M | 158.28M | 71.43M |
Cash Flow | ||||||
| Free Cash Flow | -21.66M | -29.95M | -30.67M | -16.67M | 21.97M | -38.45M |
| Operating Cash Flow | -21.66M | -29.95M | -30.56M | -16.67M | 22.11M | -38.35M |
| Investing Cash Flow | -81.00K | -81.00K | -988.90K | 0.00 | -147.73K | -3.21M |
| Financing Cash Flow | -3.96M | 0.00 | 0.00 | 0.00 | 65.88M | 75.29M |
CombiGene AB Technical Analysis
Negative
2.35
Price Trends
2.21
Negative
2.30
Negative
2.36
Negative
Market Momentum
-0.02
Negative
46.48
Neutral
33.54
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:LARK, the sentiment is Negative. The current price of 2.35 is above the 20-day moving average (MA) of 2.14, above the 50-day MA of 2.21, and below the 200-day MA of 2.36, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 46.48 is Neutral, neither overbought nor oversold. The STOCH value of 33.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:LARK.
CombiGene AB Peers Comparison
UnderperformOutperform
Sector (68)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | kr220.53M | 1.48 | -264.12% | ― | -17.80% | -11.96% | |
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% | |
54 Neutral | kr27.86M | -4.94 | -30.39% | 11.26% | ― | ― | |
45 Neutral | kr11.17M | -1.92 | -84.80% | ― | ― | 64.02% | |
43 Neutral | kr41.19M | -1.97 | ― | 8.47% | -94.12% | -25.83% | |
40 Underperform | kr18.32M | -1.19 | -88.65% | ― | 8.46% | 11.73% |
* Financial Sector Average
SE:LARK
CombiGene AB
2.08
-0.13
-5.80%
SE:2CUREX
2cureX AB
1.11
0.77
226.47%
SE:STABL
Stayble Therapeutics AB
0.17
-0.39
-69.11%
SE:EXPRS2
ExpreS2ion Biotech Holding AB
5.19
-17.21
-76.83%
SE:SPRINT
Sprint Bioscience AB
2.09
1.40
203.34%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.